Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 12.14
(2.53%)
CNY 12.14
(2.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.96 Billion CNY | -8.68% |
| 2022 | 6.53 Billion CNY | -14.27% |
| 2021 | 7.62 Billion CNY | 37.97% |
| 2020 | 5.52 Billion CNY | 27.01% |
| 2019 | 4.35 Billion CNY | -5.71% |
| 2018 | 4.61 Billion CNY | -16.98% |
| 2017 | 5.55 Billion CNY | 29.1% |
| 2016 | 4.3 Billion CNY | 289.18% |
| 2015 | 1.1 Billion CNY | -35.59% |
| 2014 | 1.71 Billion CNY | -2.7% |
| 2013 | 1.76 Billion CNY | 24.94% |
| 2012 | 1.41 Billion CNY | 181.28% |
| 2011 | 502.16 Million CNY | 5.49% |
| 2010 | 476.01 Million CNY | 31.97% |
| 2009 | 360.68 Million CNY | 1.62% |
| 2008 | 354.93 Million CNY | -1.95% |
| 2007 | 361.98 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 5.93 Billion CNY | 0.24% |
| 2024 Q1 | 5.95 Billion CNY | -0.2% |
| 2024 Q2 | 5.92 Billion CNY | -0.53% |
| 2023 Q4 | 5.96 Billion CNY | -8.24% |
| 2023 FY | 5.96 Billion CNY | -8.68% |
| 2023 Q1 | 6.49 Billion CNY | -0.56% |
| 2023 Q2 | 6.45 Billion CNY | -0.68% |
| 2023 Q3 | 6.5 Billion CNY | 0.76% |
| 2022 Q4 | 6.53 Billion CNY | 4.42% |
| 2022 FY | 6.53 Billion CNY | -14.27% |
| 2022 Q2 | 7.29 Billion CNY | -2.19% |
| 2022 Q3 | 6.25 Billion CNY | -14.17% |
| 2022 Q1 | 7.45 Billion CNY | -2.2% |
| 2021 Q3 | 7.17 Billion CNY | 0.26% |
| 2021 FY | 7.62 Billion CNY | 37.97% |
| 2021 Q4 | 7.62 Billion CNY | 6.22% |
| 2021 Q1 | 5.59 Billion CNY | 1.24% |
| 2021 Q2 | 7.15 Billion CNY | 27.96% |
| 2020 Q1 | 5.34 Billion CNY | 22.98% |
| 2020 Q4 | 5.52 Billion CNY | -2.58% |
| 2020 FY | 5.52 Billion CNY | 27.01% |
| 2020 Q2 | 5.57 Billion CNY | 4.14% |
| 2020 Q3 | 5.67 Billion CNY | 1.8% |
| 2019 Q3 | 4.4 Billion CNY | 5.94% |
| 2019 Q4 | 4.35 Billion CNY | -1.24% |
| 2019 Q1 | 4.71 Billion CNY | 2.27% |
| 2019 Q2 | 4.15 Billion CNY | -11.88% |
| 2019 FY | 4.35 Billion CNY | -5.71% |
| 2018 Q1 | 5.24 Billion CNY | -5.54% |
| 2018 Q3 | 4.79 Billion CNY | -15.54% |
| 2018 FY | 4.61 Billion CNY | -16.98% |
| 2018 Q4 | 4.61 Billion CNY | -3.69% |
| 2018 Q2 | 5.67 Billion CNY | 8.04% |
| 2017 Q2 | 4.78 Billion CNY | -6.42% |
| 2017 Q3 | 4.82 Billion CNY | 0.85% |
| 2017 Q4 | 5.55 Billion CNY | 15.12% |
| 2017 FY | 5.55 Billion CNY | 29.1% |
| 2017 Q1 | 5.11 Billion CNY | 18.83% |
| 2016 Q1 | 1.1 Billion CNY | 0.15% |
| 2016 FY | 4.3 Billion CNY | 289.18% |
| 2016 Q4 | 4.3 Billion CNY | 11.72% |
| 2016 Q2 | 2.01 Billion CNY | 81.86% |
| 2016 Q3 | 3.85 Billion CNY | 91.25% |
| 2015 Q1 | 1.62 Billion CNY | -5.24% |
| 2015 Q4 | 1.1 Billion CNY | 3.29% |
| 2015 FY | 1.1 Billion CNY | -35.59% |
| 2015 Q2 | 1.62 Billion CNY | 0.12% |
| 2015 Q3 | 1.07 Billion CNY | -34.27% |
| 2014 Q3 | 1.64 Billion CNY | -9.55% |
| 2014 Q2 | 1.82 Billion CNY | 1.13% |
| 2014 Q1 | 1.8 Billion CNY | 2.04% |
| 2014 FY | 1.71 Billion CNY | -2.7% |
| 2014 Q4 | 1.71 Billion CNY | 4.25% |
| 2013 Q1 | 1.4 Billion CNY | -0.42% |
| 2013 FY | 1.76 Billion CNY | 24.94% |
| 2013 Q2 | 1.3 Billion CNY | -7.28% |
| 2013 Q4 | 1.76 Billion CNY | -1.8% |
| 2013 Q3 | 1.79 Billion CNY | 37.79% |
| 2012 FY | 1.41 Billion CNY | 181.28% |
| 2012 Q1 | 578.64 Million CNY | 15.23% |
| 2012 Q2 | 670.25 Million CNY | 15.83% |
| 2012 Q3 | 813.27 Million CNY | 21.34% |
| 2012 Q4 | 1.41 Billion CNY | 73.68% |
| 2011 Q3 | 527.1 Million CNY | 2.62% |
| 2011 Q1 | 326.39 Million CNY | -31.43% |
| 2011 FY | 502.16 Million CNY | 5.49% |
| 2011 Q4 | 502.16 Million CNY | -4.73% |
| 2011 Q2 | 513.62 Million CNY | 57.37% |
| 2010 Q3 | 414.08 Million CNY | -0.89% |
| 2010 FY | 476.01 Million CNY | 31.97% |
| 2010 Q2 | 417.81 Million CNY | 0.0% |
| 2010 Q4 | 476.01 Million CNY | 14.96% |
| 2009 Q4 | 360.68 Million CNY | 0.0% |
| 2009 FY | 360.68 Million CNY | 1.62% |
| 2008 FY | 354.93 Million CNY | -1.95% |
| 2007 FY | 361.98 Million CNY | 0.0% |